Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBS-147 in healthy adults
NCT07335913Phase 1Recruiting
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SBS-147 in acute pain (2 arms). Primary endpoints: Adverse Events (Single Ascending Dose) at 8 days and Adverse Events (Multiple Ascending Dose) at 14 days. Started Jan 2026; status: recruiting.
02
Drugs
SBS-147
03
Conditions
acute pain
Beyond the preview
Go deeper on NCT07335913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335913.